FIELD: chemistry.
SUBSTANCE: invention relates to biochemistry and represents composition of antibodies for application in method of treatment of malignant neoplasm in a subject who had preceding course of treatment with application of antibody against human EGFR or malignant neoplasm, resistant or partially resistant to treatment with, at least, one other antibody against human EGFR, selected from the group, consisting of cetuximab, panitumumab, zalutumumab, nimotuzumab, ICR62, mAb806, matuzumab and antibodies, capable of binding the same epitope as any other of mentioned antibodies, with said composition of antibodies containing at least first molecule of antibody against human EGFR and second molecule of antibody against human EGFR and its application.
EFFECT: invention makes it possible to realise effective therapy of the second line of cancer, which does not respond to preceding treatment.
57 cl, 47 dwg, 19 tbl, 25 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS OF RECOMBINANT ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODIES | 2008 |
|
RU2488596C2 |
| SPECIFIC BINDING PROTEINS AND APPLICATIONS THEREOF | 2010 |
|
RU2549678C2 |
| SPECIFIC BINDING PROTEINS AND APPLICATIONS THEREOF | 2010 |
|
RU2673724C2 |
| EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY | 2013 |
|
RU2652880C2 |
| BINDING MOLECULE SPECIFIC FOR HER3, AND THEIR APPLICATIONS | 2012 |
|
RU2620068C2 |
| COVALENT DIANTIBODIES AND USE THEREOF | 2009 |
|
RU2593720C2 |
| ANTIBODY SITES SPECIFICALLY BINDING EGFRVIII | 2014 |
|
RU2696892C2 |
| ANTI-TUMOUR ANTIGEN ANTIBODY AND METHODS OF APPLICATION | 2011 |
|
RU2598711C2 |
| ANTIBODIES SPECIFICALLY BOUND TO EPIDERMAL GROWTH FACTOR RECEPTORS | 2009 |
|
RU2518239C2 |
| BISPECIFIC ANTIGEN-BINDING PROTEIN EGFR/CD16 | 2019 |
|
RU2792240C2 |
